Affordable Access

Access to the full text

Serum selenium and pancreatic cancer: a prospective study in the Prostate, Lung, Colorectal and Ovarian Cancer Trial cohort

Authors
  • Chatterjee, Sharmila1
  • Combs, Gerald F. Jr.2
  • Chattopadhyay, Amit3, 4
  • Stolzenberg-Solomon, Rachael1
  • 1 National Cancer Institute, Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, 9609 Medical Center Drive, Rockville, MD, 20850, USA , Rockville (United States)
  • 2 Grand Forks Human Nutrition Research Center, 2420 2nd Ave N, ARS/USDA, Grand Forks, ND, 58203, USA , Grand Forks (United States)
  • 3 Case Western Reserve University, School of Dental Medicine, Cleveland, OH, 44106, USA , Cleveland (United States)
  • 4 La Trobe University Rural Health School, La Trobe, Melbourne, Australia , Melbourne (Australia)
Type
Published Article
Journal
Cancer Causes & Control
Publisher
Springer-Verlag
Publication Date
Mar 26, 2019
Volume
30
Issue
5
Pages
457–464
Identifiers
DOI: 10.1007/s10552-019-01147-5
Source
Springer Nature
Keywords
License
Yellow

Abstract

PurposePancreatic cancer(PCa) is one of the most lethal cancers with few known consistent nutrition-related risk factors. Epidemiologic associations between the trace element selenium and PCa are inconsistent. This study examined the association of pre-diagnostic serum selenium with incident PCa.MethodsWe conducted a nested case–control study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Study (PLCO) cohort of men and women 55–70 years old at baseline (1993–2001). In total, 303 PCa cases developed during the 17-year follow-up period (1993–2009). We selected two controls (n = 606) for each case who were alive at the time the case was diagnosed who were matched on age, sex, race, and date of blood draw. We used conditional logistic regression analysis to calculate the odds ratio (OR) and 95% confidence intervals (CI) adjusting for smoking status and diabetes mellitus.ResultsMean serum selenium concentrations were slightly lower in cases (mean, 95% CI: 139.0 ng/ml, 135.6–138.9) compared to controls (142.5 ng/ml, 140.4–142.4, p = 0.08). Overall, serum selenium was not associated with PCa risk (continuous OR: 0.66; 0.32–1.37). There was no significant interaction by sex, smoking, diabetes, or follow-up time (p > 0.05).ConclusionOur results do not support the hypothesis that serum selenium is associated with PCa risk.

Report this publication

Statistics

Seen <100 times